Piperlongumine inhibits NF‐κB activity and attenuates aggressive growth characteristics of prostate cancer cells
S Ginzburg, KV Golovine, PB Makhov, RG Uzzo… - The …, 2014 - Wiley Online Library
BACKGROUND Elevated NF‐κB activity has been previously demonstrated in prostate cancer
cell lines as hormone‐independent or metastatic characteristics develop. We look at the …
cell lines as hormone‐independent or metastatic characteristics develop. We look at the …
IL27 signaling serves as an immunologic checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma
…, D Zhigarev, A Marchenko, S Khoziainova, P Makhov… - Cancer discovery, 2022 - AACR
HCC, the most common form of liver cancer, is characterized by a poor survival rate and
limited treatment options. The discovery of a novel IL27-dependent mechanism controlling …
limited treatment options. The discovery of a novel IL27-dependent mechanism controlling …
[HTML][HTML] IL-27 receptor-regulated stress myelopoiesis drives abdominal aortic aneurysm development
…, T Aghayev, AR Fatkhullina, P Makhov… - Nature …, 2019 - nature.com
Abdominal aortic aneurysm (AAA) is a prevalent life-threatening disease, where aortic wall
degradation is mediated by accumulated immune cells. Although cytokines regulate …
degradation is mediated by accumulated immune cells. Although cytokines regulate …
[HTML][HTML] Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung …
Non-small cell lung cancer (NSCLC) has limited treatment options. Expression of the RNA-binding
protein (RBP) Musashi-2 (MSI2) is elevated in a subset of non-small cell lung cancer (…
protein (RBP) Musashi-2 (MSI2) is elevated in a subset of non-small cell lung cancer (…
[HTML][HTML] PPP2R2A prostate cancer haploinsufficiency is associated with worse prognosis and a high vulnerability to B55α/PP2A reconstitution that triggers …
…, T Varughese, M Connors, K Johnson, P Makhov… - Oncogenesis, 2019 - nature.com
The PPP2R2A gene encodes the B55α regulatory subunit of PP2A. Here, we report that
PPP2R2A is hemizygously lost in ~42% of prostate adenocarcinomas, correlating with reduced …
PPP2R2A is hemizygously lost in ~42% of prostate adenocarcinomas, correlating with reduced …
[HTML][HTML] Minor grove binding ligands disrupt PARP-1 activation pathways
KI Kirsanov, E Kotova, P Makhov, K Golovine… - Oncotarget, 2014 - ncbi.nlm.nih.gov
PARP-1 is a nuclear enzyme regulating transcription, chromatin restructuring, and DNA
repair. PARP-1 is activated by interaction with NAD+, DNA, and core histones. Each route of …
repair. PARP-1 is activated by interaction with NAD+, DNA, and core histones. Each route of …
Unexpected activities in regulating ciliation contribute to off-target effects of targeted drugs
…, AS Nikonova, P Zhang, P Makhov… - Clinical Cancer …, 2019 - AACR
Purpose: For many tumors, signaling exchanges between cancer cells and other cells in their
microenvironment influence overall tumor signaling. Some of these exchanges depend on …
microenvironment influence overall tumor signaling. Some of these exchanges depend on …
ONC201 targets AR and AR-V7 signaling, reduces PSA, and synergizes with everolimus in prostate cancer
Androgen receptor (AR) signaling plays a key role in prostate cancer progression, and
androgen deprivation therapy (ADT) is a mainstay clinical treatment regimen for patients with …
androgen deprivation therapy (ADT) is a mainstay clinical treatment regimen for patients with …
[HTML][HTML] Regulation of VEGFR2 and AKT signaling by Musashi-2 in lung cancer
Simple Summary Lung cancer is the most common and lethal malignancy worldwide. Musashi-2
(MSI2) is an RNA-binding protein that is overexpressed in advanced NSCLC. VEGFR2 …
(MSI2) is an RNA-binding protein that is overexpressed in advanced NSCLC. VEGFR2 …
[HTML][HTML] Are all multi-targeted tyrosine kinase inhibitors created equal? An in vitro study of sunitinib and pazopanib in renal cell carcinoma cell lines
Objectives We examined the in vitro cellular effects of the multi-targeted receptor tyrosine
kinase inhibitors (TKIs) sunitinib and pazopanib on a series of human renal cell carcinoma (…
kinase inhibitors (TKIs) sunitinib and pazopanib on a series of human renal cell carcinoma (…